REIMS, France, September 07, 2022--(BUSINESS WIRE)--BCV announces a major step in the development and evaluation of steerable mechatronic guidewires for stroke treatment – the GECKO System. The first-in-human case was conducted by Michel Piotin, MD, PhD, head of Interventional neuroradiology at Foundation Rothschild Hospital in Paris, France.
Worldwide each year more than 12.2 million people suffer a stroke.1 The estimated global cost of stroke is over $721 billion (USD).1 A key issue in stroke treatment is speed to intervene: each minute represents nearly 2 million lost neurons.2 During stroke intervention, complications can arise that delay access to the clot and cause issues in patient recovery. 3 Current approaches can involve excessive time and devices to obtain access to the stroke location, depending on anatomical complexity.
"Because ‘time is brain,’ at BCV we developed the GECKO - a sterile, Class III single-use steerable mechatronic guidewire intended to facilitate the access and positioning of a catheter to reach the obstructing clot," said Dr Raphaël Blanc, CEO of BCV.
GECKO was designed to allow faster navigation and reduce complications, especially in tortuous vessels. GECKO is compatible with existing catheters and image-guided platforms and has potential applications in any procedure requiring guidewire access including cardiovascular, urological, gynecological, oncological and bariatric procedures.
"Physicians face many challenges with neurovascular pathologies in navigating to the treatment site rapidly and safely," said Michel Piotin. "GECKO, through its design versatility and electronic navigation, facilitates the management of complex arterial maneuvers, saving time and minimizing device exchanges. We are very pleased to be the first users and look forward to realizing the many benefits of this device on our patients."
BCV is a medical device company founded in 2016 with the mission to improve patient outcomes by providing simpler, faster and safer navigation for endovascular procedures. The company intends to submit data from the first 10 patients for a CE Mark filing in September 2022 and to hold an FDA pre-submission meeting by the end of this calendar year.
Originally developed with help from Institute of Intelligent Systems and Robotics (ISIR) at Sorbonne University-CNRS and INSERM, the core technology is mechatronic and can be integrated in robotic solutions. To learn more, please visit www.basecampvascular.com
Caution: The GECKO System is an investigational device and is not available for commercial sale, worldwide.
1 Global Stroke Fact Sheet. World Stroke Organization (WSO). 2022. www.world-stroke.org
2 Saver J, et al. Stroke. 2006;37:263–266.
3 Pilgram-Pastor SM, Piechowiak EI, Dobrocky T, et al. Stroke thrombectomy complication management Journal of NeuroInterventional Surgery 2021;13:912-917.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220907005131/en/
Amy DeWinter, Ascenda Medical Marketing - amy@ascendamed.com – +1 (919) 995-9770, media@basecampvascular.com
Nursing homes and debt collectors are billing and suing long-term-care residents’ family members and friends, demanding payments for debts these individuals don’t legally owe, consumer attorneys and federal regulators are claiming. Under federal law, nursing homes participating in Medicare and Medicaid can’t make such provisions a condition of admission or continued stay in the facility.
As the COVID-19 pandemic swept across the country in March 2020, the family of Marc Lewitinn, their 74-year-old patriarch, urged him to stay indoors. He had survived lung cancer and a stroke that left him unable to speak, and doctors were already warning that older people with his sort of medical history were especially vulnerable to the virus. He complied, more or less. But he soon felt cooped up, and one day he ventured into a crowded Starbucks near his home in Cliffside Park, New Jersey. By M
The biotech sector has had a challenging year so far. The SPDR S&P Biotech ETF is still down more than 26%, and the iShares Biotechnology ETF is down more than 19%, even though both have rallied a bit in the past few months. Contrast that with Vertex Pharmaceuticals (NASDAQ: VRTX), Axsome Therapeutics (NASDAQ: AXSM), and Neurocrine Biosciences (NASDAQ: NBIX), as all are up 20% or more this year.
If you had Covid recently, you might be better off waiting. Important factors are your risk tolerance and health profile.
Hospitals have clearly come a long way since the '70s.
Regeneron's Eylea eye-disorder drug faces competitive pressure on multiple fronts. New data could cement its dominance.
Apellis' (APLS) marketed drug, Empaveli, approved for treating paroxysmal nocturnal hemoglobinuria is driving revenues. The drug's label expansion studies also hold promise.
The FDA's PCNSDAC recommends granting marketing approval to Amylyx's (AMLX) oral drug, which slows the progression of ALS.
A Hamilton County judge didn't make a decision Thursday on whether Ohio's abortion law should remain in effect.
If we’ve learned one thing from the events of the past few months, it’s that we can’t take reproductive rights for granted. | Op-ed
Jefferies upgrades the stock and other analysts raise their price targets on Regeneron following better-than-expected data on a new formulation of the company's signature eye medication.
The newest COVID vaccine boosters aren't necessarily weak against new subvariants since it targets mutations of omicron.
FDA approves AstraZeneca's (AZN) Imfinzi combination for advanced metastatic biliary tract cancer and grants Breakthrough Therapy Designation to Pfizer's (PFE) Group B Streptococcus (GBS) vaccine.
Wastewater tests found poliovirus circulating in Nassau County, joining Rockland, Orange, Sullivan and NYC. Hochul declares state of emergency: Latest
For a very long time, Botox was synonymous with the facial injections industry — the drug made by pharma company Allergan was approved for cosmetic use in 2002 and has since become widely used as an anti-wrinkle cosmetics treatment. Botox's dominance of the anti-wrinkle market slowly started to shift with the emergence of new products on the scene. In 2019, the Federal Drug Administration (FDA) approved the Jeuveau injectable serum made by beauty company Evolus .
The vegetable was shown to lower blood sugar levels and cholesterol levels
Newly updated Pfizer and Moderna COVID-19 boosters, built to target the dominant omicron variants in the country, are now available at many retail pharmacies and hospitals across Florida.
Vascular dementia is the second most common form of dementia after Alzheimer's disease, affecting roughly one in 10 dementia patients. It occurs when other underlying conditions disrupt blood flow to the brain, resulting in inadequate oxygen and nutrients. "Inadequate blood flow can damage and eventually kill cells anywhere in the body, but the brain is especially vulnerable," explains the Alzheimer's Association.Many factors can put you at heightened risk for vascular dementia, including diabet
NEW YORK (Reuters) -New York Governor Kathy Hochul declared a disaster emergency on Friday in a bid to accelerate efforts to vaccinate residents against polio after the virus was detected in wastewater samples taken in four counties. Hochul's executive order followed the discovery of the virus last month in samples from Long Island's Nassau County, bordering the New York City borough of Queens. Earlier this year the virus was found in samples from Rockland, Orange and Sullivan counties, all north of the city.
CLAIM: A federal court order in the legal dispute over government documents held by former President Donald Trump shows President Joe Biden ordered the FBI search at Trump’s Florida home. THE FACTS: While Monday's court order from U.S. District Judge Aileen Cannon does include the phrase “as requested by the incumbent president” it’s not related to last month’s search at Mar-a-Lago. The phrase comes from a May letter from the National Archives denying Trump’s request to delay turning over documents to the FBI.